Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.66 |
| ▸ | FAAH | O00519 | 6/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRND | Q07001 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20920454 | 1.00 | MGLL (0.66) | MGLLFAAHCHRNB4CHRNA3CHRNA1 | |
| SCHEMBL25643208 | 0.92 | FAAH (0.71) | MGLLFAAH | |
| SCHEMBL20920445 | 0.92 | FAAH (0.71) | MGLLFAAH | |
| SCHEMBL25830230 | 0.92 | MGLL (0.55) | MGLLFAAHCHRNB4CHRNA3CHRNA1 | |
| SCHEMBL24970388 | 0.85 | MGLL (0.83) | MGLLFAAH | |
| SCHEMBL20920452 | 0.85 | MGLL (0.83) | MGLLFAAH | |
| SCHEMBL25830223 | 0.84 | FAAH (0.61) | MGLLFAAH | |
| SCHEMBL20920451 | 0.81 | FAAH (0.83) | MGLLFAAH | |
| SCHEMBL24970125 | 0.81 | FAAH (0.83) | MGLLFAAH | |
| SCHEMBL25643215 | 0.80 | MGLL (0.74) | MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885FAAH 33/4885CHRNB4 4068/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885FAAH 32/4885CHRNB4 4074/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885FAAH 32/4885CHRNB4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.